Aberdeen Asset Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
AL
Aberdeen Asset Management's DGX Position: Q2 2017 in Review
Aberdeen Asset Management reduced its Quest Diagnostics (DGX) stake by 11% in Q2 2017, selling an estimated $2.62M and leaving 204,699 shares worth $22.8M. The position accounts for 0.08% of the portfolio, ranked #230.
Aberdeen Asset Management first reported a position in DGX in Q2 2013 and has held it in 17 quarters since. The position peaked at $669M in Q3 2013. 643 funds tracked by Wall St. Rank hold DGX as of Q2 2017.
- Aberdeen Asset Management held 204,699 shares of Quest Diagnostics worth $22.8M as of Q2 2017.
- Aberdeen Asset Management sold 24,738 Quest Diagnostics shares in Q2 2017, an estimated $2.62M.
- Quest Diagnostics made up 0.08% of Aberdeen Asset Management's portfolio in Q2 2017, its #230 holding.
- Aberdeen Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 17 quarters since.
- Aberdeen Asset Management's Quest Diagnostics position peaked at $669M in Q3 2013.
- 643 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2017.
Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.